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Abstract 
Background: Plasmodium falciparum enolase has been shown to localize on the surface of merozoites and ookine-
tes. Immunization of mice with recombinant Plasmodium enolase (rPfeno) showed partial protection against malaria. 
Anti-rPfeno antibodies inhibited growth of the parasite in in vitro cultures and blocked ookinete invasion of mosquito 
midgut epithelium. It is hypothesized that parasite specific moonlighting functions (e.g. host cell invasion) may map 
on to unique structural elements of Pfeno. Since enolases are highly conserved between the host and the parasite, a 
parasite-specific epitope of enolase was displayed on novel protein nanoparticles produced by a halophilic Archaeon 
Halobacterium sp. NRC-1 and tested their ability to protect mice against live challenge.
Methods: By genetic engineering, a Plasmodium-enolase specific peptide sequence 104EWGWS108 with protective 
antigenic potential was inserted into the Halobacterium gas vesicle protein GvpC, a protein localized on the surface of 
immunogenic gas vesicle nanoparticles (GVNPs). Two groups of mice were immunized with the wild type (WT) and 
the insert containing recombinant (Rec) GVNPs respectively. A third group of mice was kept as un-immunized control. 
Antibody titres were measured against three antigens (i.e. WT-GVNPs, Rec-GVNPs and rPfeno) using ELISA. The protec-
tive potential was determined by measuring percentage parasitaemia and survival after challenge with the lethal 
strain Plasmodium yoelii 17XL.
Results: Rec-GVNP-immunized mice showed higher antibody titres against rPfeno and Rec-GVNPs, indicating that 
the immunized mice had produced antibodies against the parasite enolase-specific insert sequence. Challenging the 
un-immunized, WT-GVNP and Rec-GVNP-immunized mice with a lethal strain of mice malarial parasite showed sig-
nificantly lower parasitaemia and longer survival in the Rec-GVNP-immunized group as compared to control groups. 
The extent of survival advantage in the Rec-GVNP-group showed positive correlation with anti-rPfeno antibody titres 
while the parasitaemia showed a negative correlation. These results indicate that the parasite enolase peptide insert 
displayed on Halobacterium GVNPs is a good candidate as a protective antigenic epitope.
Conclusion: The work reported here showed that the parasite-specific peptide sequence is a protective antigenic 
epitope. Although antibody response of B-cells to the guest sequence in Rec-GVNPs was mild, significant advantage 
in the control of parasitaemia and survival was observed. Future efforts are needed to display multiple antigens with 
protective properties to improve the performance of the GVNP-based approach.
Keywords: Plasmodium falciparum enolase, Protective epitope, Halobacterium gas vesicles, Nanoparticles
© 2015 Dutta et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
*Correspondence:  sdassarma@som.umaryland.edu; GKJarori@gmail.com 
1 Department of Biological Sciences, Tata Institute of Fundamental 
Research, Homi Bhabha Road, Colaba, Mumbai 400005, India
2 Department of Microbiology and Immunology, Institute of Marine 
and Environmental Technology, University of Maryland School 
of Medicine, Baltimore, MD 21202, USA
Full list of author information is available at the end of the article
Page 2 of 10Dutta et al. Malar J  (2015) 14:406 
Background
Malaria is a major health problem in developing coun-
tries that caused  ~584,000 deaths in 2013 [1]. Multi-
ple drugs are available for the treatment of this disease 
and several new ones are constantly being introduced. 
However, the emergence of resistance to drugs is rap-
idly diminishing the effectiveness of current treatments 
[2]. As a result, the development of an effective vaccine 
is highly desirable as a major preventative tool. Thus far, 
efforts have been partially successful with a candidate 
vaccine, RTS,S currently in Phase-3 trials and one version 
(Mosquirix produced by GlaxoSmithKline Biologicals) 
was recently licensed by the European Medicines Agency 
for use in infants and children [3, 4].
Plasmodium has a complex life cycle and invades host 
cells at three different stages. The sporozoites invade 
hepatocytes, the merozoites invade RBCs and the ooki-
netes invade mosquito midgut epithelium [5]. The 
components of the molecular machinery involved in rec-
ognition and invasion serve as attractive vaccine candi-
dates. Several molecules involved in the invasion of RBCs 
[6], hepatocytes [7, 8] and mosquito midgut [9] have been 
tested for their protective antigenicity against malaria [3]. 
However, due to the magnitude of the challenges of the 
disease, sustained efforts are still needed for the contin-
ued identification and validation of additional novel anti-
gens with protective potential against malaria.
Apart from the antigens that express only on the sur-
face of invasive stages, certain housekeeping proteins 
have also been found to localize onto the cell surface. The 
glycolytic enzyme enolase is one such protein that is pre-
sent on both merozoite [10] and ookinete [11] cell sur-
faces. In many other pathogenic and nonpathogenic cells, 
enolase acts as a cell surface receptor for plasminogen 
to assist the cells/organism to establish or move through 
the extra-cellular matrix [12, 13]. In Plasmodium spp. 
ookinetes, surface enolase bound plasminogen helps in 
digestion of the peritrophic matrix of the mosquito mid 
gut epithelium. This function is known to map onto a 
lysine motif DKSLVK of Plasmodium falciparum enolase 
(Pfeno) [11]. On the ookinete surface, enolase also func-
tions as a ligand that recognizes specific receptors on the 
mosquito midgut epithelium [14]. Anti-Pfeno antibodies 
have been shown to block both these functions resulting 
in the disruption of parasite transmission. In merozo-
ites, its role as a protective antigen became evident from 
the observations that immunization of mice with rPfeno 
resulted in partial protection against malaria.
Further evidence for the protective antigenic ability 
of Pfeno was from the observed inhibition of parasite 
growth in in vitro cultures by anti-rPfeno antibodies [15]. 
However, the structural elements of Pfeno involved in the 
protective antigenic functions are still unknown. Since 
invasion of host cells is unique to the parasite, it is likely 
to involve a motif that is structurally dissimilar to host 
enolases. Pfeno has one such motif that is a sequence 
of five amino acids present as an insert in a surface loop 
region of the protein [16]. Interestingly, the possibility of 
the involvement of this motif in invasion related function 
was indicated by the observation that Pfeno immunized 
mice surviving lethal parasite challenge had high titres of 
antibodies directed against this region [17].
To further test the possibility of the pentapeptide insert 
being a protective epitope, gas vesicle protein nanoparti-
cles (GVNPs) were employed for antigen display and as 
a delivery vehicle [18]. Nanoparticle-based vaccines have 
certain advantages due to reduced risk compared to live 
vaccines, and enhanced protection. Biologically compat-
ible nanoparticles can simultaneously function as both an 
adjuvant and a delivery system, by presenting antigens to 
the antigen presentation cells (APCs), and as immuno-
potentiators, increasing immunogenicity without adverse 
reactogenicity [19, 20]. GVNPs are in the correct size 
range for eliciting cytotoxic T cell responses and have 
desirable surface charges and hydrophobic properties for 
interactions with APCs and phagocytes [21, 22].
A significant advantage of GVNPs as an adjuvant and 
antigen delivery system is their stability under a wide 
range of conditions and outstanding biocompatibility 
[18]. These nanoparticles maintain stability for extended 
periods of time even in the absence of a cold chain and 
have no known toxic effects in animals, either systemi-
cally or at the site of administration [23, 24]. GVNPs may 
be administered through conventional routes, by needle 
injection, subcutaneously or intraperitoneally (IP), as well 
as through alternate routes, including oral or nasal, and 
transdermally, using microneedles. These options may 
elicit both systemic and mucosal immunity, while simul-
taneously reducing costs and improving compliance.
Over the past 15 years, antigen display on GVNPs has 
been demonstrated using diverse peptide and protein 
antigens fused to the GvpC nanoparticle surface pro-
tein [18, 25–27]. The source of antigens displayed on the 
surface of GVNPs have thus far included a virus, simian 
immunodeficiency virus (SIV), two bacteria, the obligate 
intracellular pathogen Chlamydia trachomatis and the 
facultative intracellular pathogen Salmonella enterica, 
as well as the eukaryotic parasitic protozoan P. falcipa-
rum [23, 28–33]. GVNP-displayed antigenic proteins 
have ranged from secreted proteins to coat and envelope 
proteins, to transcription factors. Studies have been con-
ducted both in vitro and in vivo, with displayed antigens 
being released slowly over days, and tested by challenge 
in the case of Salmonella [32, 33].
In the present study, a highly conserved 15-amino acid 
peptide sequence from the Plasmodium moonlighting 
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protein enolase was cloned into the Halobacterium 
GVNP-display system [18]. The ability of this sequence 
displayed on GVNPs to elicit an antibody response that 
can protect against subsequent parasite challenge was 
tested in mice. The results showed that this approach 




Antibodies against rPfeno were raised in mice using in-
house facilities as described earlier [34]. HRP-conjugated 
mouse and rabbit secondary antibodies were obtained 
from AbCam. ABTS [2,2′-azino-bis(3-ethylbenzothiazo-
line-6-sulphonicacid)] was obtained from Sigma-Aldrich 
Co.
Purification of rPfeno and raising anti‑rPfeno antibodies
GST-tagged-rPfeno was expressed in Escherichia coli and 
purified as described earlier [17]. Briefly, bacterial cul-
ture overexpressing rPfeno were homogenized and clear 
supernatant was obtained by centrifugation. GST-tagged 
recombinant protein was purified by passing the super-
natant on a glutathione-Sepharose column. The protein 
was cleaved off its GST tag using thrombin. Purified 
rPfeno was recovered from the eluate. For raising antisera 
in mice, a published protocol was used as described ear-
lier [34].
Design, cloning and purification of gas vesicle 
nanoparticles
A double-stranded oligonucleotide was synthesized 
coding for a Pfeno derived 15-amino acid peptide 
(DGSKNEWGWSKSKLG, containing the Plasmodium 
104EWGWS108 epitope). The oligonucleaotide sequence 
was codon-optimized using the codon usage table for 
predicted genes in the fully sequenced Halobacterium sp. 
NRC-1 genome [35]. The synthetic DNA fragment was 
cloned into the Halobacterium sp. pSD104 vector at the 
AfeI site in gvpC [27], to construct plasmid pSD104::Eno. 
The gvpC gene region of the constructed plasmid was 
sequenced to verify the correctness of the insertion 
sequence.
Plasmid pSD104::Eno was transformed into Halobacte-
rium strain SD109, a strain that lacks the gas vesicle gene 
cluster. After lysis of cells, Rec-GVNPs displaying the 
Pfeno epitope were purified from Halobacterium SD109 
(pSD104::Eno) by flotation of the GVNP particles using 
the centrifugally accelerated procedure reported previ-
ously [36]. Presence of the GvpC-Pfeno fusion protein 
was confirmed by Western blotting using Pfeno primary 
antibody followed by alkaline phosphatase-conjugated 
goat anti-rabbit IgG secondary antibody (Sigma-Aldrich, 
St. Louis, MO, USA).
Gel electrophoresis and Western blotting
SDS-PAGE was run using the Laemmli method [37]. 
Proteins were resolved on a 10 % SDS-PAGE and visual-
ized by staining with Coomassie Brilliant Blue R-250. For 
Western blotting, proteins were separated by SDS-PAGE 
(10 % gels) and transferred to a PVDF membrane using 
semi-dry western transfer apparatus (Trans-blot SD-
cell, Bio-Rad Laboratories, Inc., Hercules, CA, USA) at a 
constant voltage of 18 volts for 50 min. The membranes 
were blocked with 5 % skimmed milk in phosphate buff-
ered saline containing 0.05 % Tween-20 for 2 h. The blots 
were treated with primary antibody. For the detection 
of Plasmodium yoelii (Pyeno) or Pfeno derived peptide 
sequence in Rec-GVNPs, anti-rPfeno antibodies were 
used at 1:1000 dilutions. Anti-rPfeno antibodies were 
raised in mice as described earlier [34]. Incubation with 
the primary antibody was followed by washing and incu-
bation with HRP-conjugated secondary antibody. The 
immunoblots were developed using di-anilino-benzene 
substrate.
Immunization of mice with nanoparticles
Experiments were performed on male Swiss mice aged 
6–8  weeks. Mice were injected with 100 μg of WT-
GVNPs or Rec-GVNPs in Freund’s complete adjuvant 
intra-peritoneally. Subsequent booster doses of 100 μg 
WT or Rec-GVNPs in Freund’s incomplete adjuvant 
were administered at 21 days interval. Ten days after the 
second booster sera from these animals were collected 
by partial retro-orbital bleed to assay for their reactivity 
against rPfeno, WT-GVNPs and Rec-GVNPs. All immu-
nized mice and an un-immunized control group of mice 
were challenged with equal numbers of (approximately 
106) P. yoelii 17XL infected RBCs and their survival as 
well as percent parasitaemia was monitored as described 
earlier [15].
ELISA
ELISAs were performed as previously described [34]. 
Briefly, the antigen in a volume of 100 μl was coated onto 
a Maxisorp immunoplate and incubated at 37 °C for 2 h. 
This was followed by washing the plate and blocking the 
wells with 5 % skimmed milk in PBST (10 mM Na2HPO4, 
1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl containing 
0.05 % Tween-20; pH 7.4) for 1 h at room temperature or 
4 °C overnight. The blocking solution was discarded and 
the wells were washed with PBST three times for 5 min 
each. 100 μl of primary antibody (dilution varied accord-
ing to experiment) was added to each well and incubated 
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at room temperature for 1 h. The solution was discarded 
and the wells were washed with PBST three times to 
remove any unbound antibody. This was followed by the 
addition of HRP-conjugated anti-mouse secondary anti-
body at a dilution of 1:1000 and incubated at room tem-
perature for 45 min. The solution was discarded and the 
wells were washed with PBST thrice. 200 μl of ready-to-
use ABTS substrate was added into each well. The colour 
was allowed to develop for 10–15  min and absorbance 
was measured as an optical density (OD) at 405 nm on a 
Tecan Plate Reader.
For the measurements of anti-WT-GVNP (or anti-
Rec-GVNP) antibody titres in serum, ELISA plates were 
coated with 1 µg of the respective antigen and sera were 
diluted 1:1000. For anti-rPfeno antibody titer determina-
tion, plates were coated with 100 ng of rPfeno and serum 
dilutions used were 1:100.
Statistical analysis
For the comparison of survival data, Kaplan–Meier Log-
Rank test was done. For all other analysis, Student’s t test 
was used (computed using Excel).
Results
Cloning and preparation of recombinant GVNPs 
from Halobacterium sp. NRC‑1
In order to display the Pfeno antigenic epitope on 
GVNPs, an oligonucleotide coding for a Pfeno derived 
peptide containing the desired EWGWS sequence within 
an 15-amino acid sequence (DGSKNEWGWSKSKLG) 
was selected. This peptide sequence was BLASTed 
against the mouse genome (GenBank taxid:10088) to 
detect if there are homologous sequences present. How-
ever, no significant homology in mammalian genome 
was found. Use of a longer sequence that encompassed 
the conserved residues on either side of EWGWS 
ensured that the epitope was displayed in the proper 
Pfeno context. The oligonucleotide corresponding to the 
15aa peptide was inserted at an AfeI site in gvpC in the 
Halobacterium sp. pSD104 vector, which contains the 
complete 14-gene gas vesicle gene cluster. The resulting 
plasmid pSD104::Eno was transformed into Halobacte-
rium strain SD109, deleted for entire the gas vesicle gene 
cluster. GVNPs were purified from the resulting Halo-
bacterium SD109 (pSD104::Eno) strain and wild-type 
strain NRC-1 by centrifugally accelerated flotation using 
a published procedure [27].
Cloned sequence is recognized by anti‑rPfeno antibodies
Wild-type nanoparticles (WT-GVNPs) differ from 
recombinant nanoparticles (Rec-GVNPs) in the pres-
ence of the Pfeno derived peptide 104EWGWS108 in the 
gvpC gene. For immuno-detection of this epitope in 
Rec-GVNPs and absence in WT-GVNPs for, samples of 
purified WT and Rec-GVNPs were analysed on a 10  % 
SDS-PAGE gel. P. yoelii cell extract (soluble fraction) was 
included as a positive control for antibody recognition 
of enolase. The protein profiles of WT and Rec-GVNPs 
are shown in Fig.  1a. Western blots with anti-rPfeno 
antibodies (mouse) are shown in Fig.  1b, c. Antibod-
ies recognized enolase (MW  ~50  kDa) in the parasite 
extract. Enolase positive bands at  ~20  kDa and around 
35–40 kDa were also observed in P. falciparum extracts 
and were identified by mass spectrometry to be the prod-
ucts of proteolysis of native 50  kDa form [38]. In the 
nanoparticle lanes, Western blot showed an enolase posi-
tive band with an apparent molecular mass of  ~71  kDa 
(marked with *). This was present only in Rec-GVNPs 
and was absent in WT-GVNPs. The positive reactivity of 
the ~71 kDa band with anti-rPfeno polyclonal antibodies 
is due to the presence of the cloned sequence EWGWS 
in the GvpC-Eno protein found on the GVNPs and con-
firms the presence of the engineered peptide insert in the 
Rec-GVNPs.
Immunogenicity and antibody specificity profile 
of nanoparticles
For comparative analysis of the antibody response, 
two groups of mice were immunized with WT-GVNPs 
(n = 5) and Rec-GVNPs (n = 10), respectively. A group 
of five mice (n = 5) were kept as un-immunized controls. 
For immunization, 100  µg of GVNPs in complete Fre-
und’s adjuvant were injected. Subsequently, two booster 
doses (100  µg GVNPs in Freund’s incomplete adjuvant) 
were administered at an interval of 21 days. Serum sam-
ples were collected by partial retro-orbital bleed 10 days 
after second booster dose.
Antibody responses to the two classes of particles (WT-
GVNPs or Rec-GVNPs) were quantified by ELISA using 
one or the other particle as the antigen. ELISA measure-
ments where the plates were coated with WT-GVNPs 
(1μg/well), both serum samples gave similar titres of anti-
bodies (Fig. 2a) indicating that both groups of mice pro-
duced antibodies against the GVNP component proteins. 
However, when Rec-GVNPs were used as the antigen, 
higher antibody titres were observed with serum samples 
derived from Rec-GVNP-immunized mice (Fig. 2b). This 
was indicative of antibody response against the Pfeno 
derived peptide displayed on Rec-GVNPs. However, such 
a differential antibody response could also arise due to 
some contaminant in purified Rec-GVNPs. As expected, 
serum samples from un-immunized control mice did not 
show any reactivity towards either of the particles when 
used as antigens (Fig. 2a, b). Lack of differential reactiv-
ity towards WT-GVNPs between the two types of serum 
samples (raised against WT-GVNPs and Rec-GVNPs) 
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suggested that coated WT-GVNPs reacted with the anti-
bodies arising against similar epitopes in both samples. 
However, the higher reactivity towards Rec-GVNPs in 
serum samples from Rec-GVNP immunized mice sug-
gested that a fraction of antibodies was directed against 
the cloned sequence DGSKNEWGWSKSKLG contain-
ing EWGWS, the parasite specific insert motif of Pfeno. 
To determine whether this is indeed the case, the reactiv-
ity of sera using rPfeno as an antigen was measured.
Immunization with recombinant nanoparticles generate 
antibody responses specific to rPfeno
To assess the immunogenic potential of Halobacterium 
gas vesicle nanoparticles displaying the Pfeno derived 
peptide in the mouse system, sera from WT and Rec-
GVNP-immunized mice were subjected to ELISA using 
rPfeno as an antigen. 100 ng of rPfeno was coated onto 
each well of the plate and 1:100 diluted sera from immu-
nized and control mice was used as primary antibody. 
Results of the experiment for serum reactivity of each 
individual mouse are shown in Fig. 3a. Figure 3b shows 
the average values for all the animals in a single treatment 
group. Anti-rPfeno antibody titres were found to be sig-
nificantly higher in the case of Rec-GVNP-immunized 
mice as compared to the WT-GVNP group (Fig.  3b). 
Although, it was expected that displayed Pfeno peptide 
in the context of gas vesicle nanoparticles (Rec-GVNPs) 
would elicit a robust antibody response, observations 
indicate the antibody response was relatively mild which 
is not unexpected, given the proportionate size of the 
5 amino acid sequence compared to the entire GVNP 
complex.
Protective effect of immunization with Pfeno peptide
To evaluate whether the antibodies against the parasite 
specific insert sequence of Pfeno are protective under 
in  vivo conditions, all three groups of mice, viz. un-
immunized (control), WT and Rec-GVNP-immunized 
mice, were challenged with equal numbers of iRBCs 
(approximately 106) infected with asynchronous P. yoelii 
17XL (lethal strain), which were isolated from infected 
mice. The parasites were injected 10  days after the sec-
ond booster dose of nanoparticles. Parasitaemia in these 
mice was monitored on every second day post parasite 
injection to assess the effect of immunization on para-
site growth. Percent parasitaemia in the control groups 
of mice (i.e. un-immunized and WT-GVNP-immunized) 
was much higher as compared to Rec-GVNP-immu-
nized group. Statistical analysis of data using Student’s 
t-test showed that on days 4 and 6 (post parasite chal-
lenge), WT-GVNP-immunized group had significantly 
higher percent parasitaemia (p  =  0.001) as compared 
Fig. 1 Protein profiles of the WT and Rec-GVNPs and their reactivity towards anti-rPfeno antibodies. a Coomassie stained 10 % SDS-PAGE gel show-
ing protein profiles of P. yoelii cytosolic extract, WT-GVNPs and Rec-GVNPs. Western blots of b P. yoelii extract and c WT and Rec GVNPs using anti-
rPfeno antibodies. Antibodies recognized Pyeno (~50 kDa) and a positive band observed at ~71 kDa (marked with asterisk) in Rec-GVNPs indicates 
the presence of parasite enolase derived peptide (EWGWS) insert
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to Rec-GVNP-immunized group. The extent of parasite 
growth retardation in Rec-GVNP immunized mice was 
approximately 2- to 2.5-fold as compared to the ones 
immunized with WT-GVNPs (Fig. 4a).
These mice were also monitored for their survival. Sur-
vival profiles for all three groups are shown in Fig.  4b. 
Rec-GVNP-injected mice survived significantly longer 
compared to WT-GVNP-treated and un-immunized 
control groups. As stated above, although the antibody 
titres of anti-EWGWS in Rec-GVNP immunized mice 
were moderate, observation of significant retardation in 
parasite growth and prolongation of survival support the 
view that the Pfeno derived peptide constitutes a protec-
tive antigenic epitope against malaria.
Percent parasitaemia and survival profile correlates 
with anti‑rPfeno antibody titres in Rec‑GVNP immunized 
mice
Since each Rec-GVNP-injected mouse had a differ-
ent degree of reactivity with rPfeno on the ELISA based 
assay (Fig.  3a), it indicated that the antibody titres 
against rPfeno in each immunized animal was differ-
ent. If EWGWS was the protective epitope, titres of 
antibodies against it should have a positive correlation 
with survival and negative with percent parasitaemia. 
Anti-rPfeno antibody titres as measured by ELISA were 
plotted against the number of post parasite challenge 
days that an animal survived (Fig.  5a). The plot showed 
a positive correlation (R2 =  0.64) (albeit weak) between 
survival and antibody titres. Antibody titre vs. percent 
parasitaemia was also plotted. It was expected that anti-
EWGWS antibodies would inhibit parasite growth if this 
sequence constitutes a protective epitope. The plot did 
show a negative correlation (Fig. 5b), i.e. the increase in 
antibody titres interfered with the growth and division of 
the parasite resulting in a negative correlation between 
percent parasitaemia and anti-rPfeno antibody titres. A 
negative correlation between percent parasitaemia and 
number of days a mouse survived post-challenge of the 
lethal parasite was also observed (Fig. 5c), indicating that 
the parasite load is a critical factor in the survival of the 
mice. These results suggested that anti-EWGWS anti-
bodies inhibited the growth of the parasite, resulting in 
diminished parasitaemia, and that in turn brought about 
enhanced survival.
Discussion
Development of an effective vaccine and delivery sys-
tem for malaria is urgent. While a large number (~100) 
of candidate malaria vaccines are being tested, most are 
based on only a handful of antigens and standard modes 
of immunization [3, 39]. Given the prevalence of the dis-
ease, there is a compelling need for identifying additional 
antigens with protective properties and testing novel dis-
play and delivery systems. One such antigen candidate is 
enolase which has been shown to possess invasion func-
tions when present on the surfaces of Plasmodium spp. 
merozoites and ookinetes [11, 14, 15]. The potential of a 
short peptide sequence (EWGWS) derived from the par-
asite was displayed on Halobacterium gas vesicle nano-
particles for studying its protective antigenic properties. 
The results obtained are encouraging and warrant fur-
ther studies, especially since the high stability of GVNPs 
provides the potential for distribution of a vaccine in the 
absence of a cold-chain [18].
For an effective vaccine, it is essential that the antigen 
induces a long lasting robust immune response (resulting 
Fig. 2 ELISA for the determination of antibody titres in serum 
samples derived from control (un-immunized), WT-GVNP and 
Rec-GVNP-immunized mice. Plates were coated with (a) WT-GVNPs 
and (b) Rec-GVNPs. The error bars represent standard deviation for 
the triplicates. Control (un-immunized) sera showed no reactivity. 
Reactivity towards WT-GVNPs was similar in the two groups (p > 0.21) 
(WT-GVNP and Rec-GVNP-immunized) a; however, reactivity towards 
Rec-GVNPs was significantly higher (p < 0.002) b. Number of mice in 
each group were—Control n = 5, WT-GVNP n = 5; Rec-GVNP n = 10. 
Seven mice with highest anti-rPfeno antibody titres in the Rec-GVNP 
immunized group were selected for the parasite challenge
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in secretion of antibodies and generation of memory 
B-cells) and activation of CD8+  T-cells that constitutes 
a significant challenge. Use of a combination of multiple 
antigens in conjunction with different adjuvants have 
not been very successful in obtaining strong B and T cell 
responses [3]. Effective induction of immune activation 
was observed in several recent studies where nanoparti-
cle based vaccines were used [40–42]. The strategy used 
in this study, was to insert a Plasmodium-specific anti-
genic peptide sequence in a protein that is a component 
of the GVNPs shown to be released slowly in the immune 
system [29, 30]. Presence and display of this sequence 
in Rec-GVNP was verified by the observed reactivity of 
anti-rPfeno antibodies in Western blots (Fig. 1c) as well 
as in ELISAs (Fig. 3).
Mice that were immunized with Rec-GVNPs having 
the Pfeno epitope, when challenged with P. yoelii 17XL 
(~106 iRBCs per animal), showed significantly slower 
growth of parasitaemia as compared to the control and 
WT-GVNP-immunized cohorts (Fig.  4a). Inhibition 
of parasite growth is likely to be due to the antibody 
response directed against the cloned parasite enolase 
sequence in the Rec-GVNP-immunized mice. Further, 
monitoring these mice for survival showed significant 
prolongation of survival as compared to other groups. 
Correlation between anti-rPfeno antibody titres and 
parasitaemia as well as survival for individual mice was 
also analysed. As shown in Fig. 5a, b, a positive correla-
tion was found with survival, i.e. higher levels of anti-
rPfeno antibodies led to longer survival of animals. 
Conversely, a negative correlation was observed where 
higher antibody titres led to reduction in parasitaemia. 
As expected, a mouse with higher parasitaemia died 
earlier (Fig. 5c). These results strongly support the con-
clusion that the Pfeno sequence EWGWS is a protective 
epitope.
Fig. 3 Anti-rPfeno antibody titres in serum samples derived from un-immunized (C1-C5), WT-GVNPs (W1-W5) and Rec-GVNP (R1-R10) immunized 
mice. a ELISA for the measurement of anti-rPfeno antibody titres in serum obtained from individual mice. b Bar graph showing average anti-rPfeno 
antibody titres. Antibody response was significantly higher in Rec-GVNP-immunized mice as compared to WT-GVNP-immunized ones (p < 0.048)
Fig. 4 Rec-GVNP-immunized mice showed low parasitaemia and longer survival as compared to un-immunized and WT-GVNP-immunized groups. 
All three groups of mice were injected intra-peritoneally with equal number of P. yoelii 17XL iRBCs (approximately 106). a % Parasitaemia significantly 
differed on days 4 and 6 for the Rec-GVNP immunized mice (p = 0.001); b survival profile of mice as a function of days
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Functionally, the -EWGWS- motif is likely to be 
involved in interaction with the cell surface receptors 
in RBCs and mosquito midgut epithelial cells. Recent 
studies on the functional role of the motif in the bio-
chemical activity of the enzyme suggested that it could 
stabilize the apo-enzyme in an active form [43]. Although 
immunization with Pfeno derived peptide conferred 
longer survival and controlled the growth of parasitae-
mia, the overall effect was rather modest. This was also 
evident from the observed titres of antibodies against 
rPfeno in Rec-GVNP-immunized mice (Fig.  3a, b). and 
likely reflects the small size of the antigenic epitope.
In recent studies, the results with Halobacterium 
GVNPs have been encouraging for the display of Sal-
monella, Chlamydia, SIV antigens, as well as Plasmo-
dium CSP [18, 23, 28–33]. Although the parasite specific 
unique insert EWGWS in Pfeno is likely to be a protec-
tive antigenic epitope, future efforts should be directed at 
engineering nanoparticle preparations that elicit stronger 
antibody responses in order to achieve a complete clear-
ance of the parasite. A promising approach in this regard 
may be to display multiple antigens that could lead to a 
more protective formulation [27, 44].
It has been noted that people in endemic areas have the 
potential to develop protective immunity following mul-
tiple episodes of malaria. IgGs isolated from such people 
inhibit parasite growth in  vitro [45] and passive trans-
fer to malaria patients can lead to recovery [46]. Conse-
quently, identification of antigens that are recognized by 
serum antibodies derived from immune individuals but 
not by malaria patients has been one approach to identi-
fying vaccine candidates. Using such differential screens, 
new antigens like PfP0 [47] and PfSEA-1 [48] with pro-
tective antigenic properties have been identified and offer 
further opportunities for application using the GVNP 
technology.
Conclusions
Data presented here demonstrate that a parasite-spe-
cific peptide sequence derived from Pfeno and displayed 
on GVNPs is able to elicit an antibody response against 
enolase when injected in mice. Anti-peptide antibodies 
elicited protective responses as evident from low para-
sitaemia and enhanced survival of Rec-GVNP-immu-
nized mice. These experiments support the existence of 
a protective antigenic epitope in parasite enolase and our 
ability to display and deliver this sequence on GVNPs. 
Further efforts are needed to enhance the immunogenic-
ity and protective potential of this potential malaria vac-
cine candidate.
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